TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2548905

Group type: EXPERIMENTAL
Intervention: 0.25 micrograms alpha‐calcoid given orally twice daily (n = 9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 25 micrograms calcitonin given subcutaneously 30 times (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 30
Study: 790961

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29206755

Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 27
Study: 25724354

Group type: EXPERIMENTAL
Intervention: 15-min refresher BLS training
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no refresher training)
Number of subjects: 112
Study: 23769863

Group type: EXPERIMENTAL
Intervention: Inhaled extra-fine beclomethasone/formoterol (I‐EF‐BDP/F)
Number of subjects: 59
Study: 21195292

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 178
Study: 19395059

Group type: EXPERIMENTAL
Intervention: Suction technique (anterior rhinoscopy and suction)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water technique (water poured into kidney tray)
Number of subjects: 40
Study: 17175304

Group type: EXPERIMENTAL
Intervention: Sirolimus-based calcineurin inhibitor (CNI)-free regimen (sirolimus 5 mg daily starting postoperative day 3, mycophenolate mofetil 1 gm twice a day, methylprednisolone 500 mg intraoperatively, prednisone 30 mg daily tapered to 10 mg daily at 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacrolimus-based steroid-free regimen (tacrolimus 0.075 mg/kg twice a day, mycophenolate mofetil 1 g twice a day, methylprednisolone 500 mg, 250 mg, and 125 mg from days 0 to 2, then no further steroids)
Number of subjects: 0
Study: 12927652

Group type: COMPARATOR
Intervention: d-amphetamine 0 mg (placebo)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: d-amphetamine (all doses)
Number of subjects: 8
Study: 10620000

Group type: EXPERIMENTAL
Intervention: Nitroglycerin-releasing 'active' patches (approx. 0.4 mg hour‐1 nitroglycerin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study: 8620093

Group type: EXPERIMENTAL
Intervention: Chinese herbal therapy (Zemaphyte) for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chinese herbal therapy (Zemaphyte)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 0
Study: 1526863

Group type: EXPERIMENTAL
Intervention: Episcleral plaque radiotherapy (EPRT)
Number of subjects: 85
Study: 3919754

Group type: EXPERIMENTAL
Intervention: Topical cream containing 4% sodium cromoglycate (SCG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 29637808

Group type: EXPERIMENTAL
Intervention: Proper cleaning and inspection of slicers (defined as disassembling, cleaning, and sanitizing every 4 hours)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Slicers being undamaged
Number of subjects: 298
Study: 26715234

Group type: EXPERIMENTAL
Intervention: 30‐min nap (30‐NAP)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10‐min nap (10‐NAP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Total sleep deprivation (NO‐NAP)
Number of subjects: 31
Study: 24946630

Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion applied once a day for 15 days, targeting specific acupoints (Hegu, Quchi, Yanglingquan, Zusanli, Xuehai).
Number of subjects: 68

Group type: COMPARATOR
Intervention: Medication group used triamcinolone acetonide cream externally and locally, twice a day for 15 days.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups underwent treatment for 3 sessions, with hemorheology tests and radioimmunoassays for IL-2, IL-6, IL-10, and TNF-alpha levels.
Number of subjects: 68
Study: 23066737

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE) - 2 × 8 min at 100% peak power output (PPO) with 30 s passive recovery intervals
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE) - 22 min at 60% of PPO
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 13
Study: 20503055

Group type: EXPERIMENTAL
Intervention: LH/TL+TH (live high/train low plus train high)
Number of subjects: 17

Group type: COMPARATOR
Intervention: TH (train high)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: LH/TL+TH
Number of subjects: 17
Study: 18041396

Group type: EXPERIMENTAL
Intervention: Noninvasive Mechanical Ventilation (MV) in patients with Cst > 0.025 L/cm H2O
Number of subjects: 387

Group type: COMPARATOR
Intervention: Invasive Mechanical Ventilation (MV) in patients with Cst > 0.025 L/cm H2O
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Noninvasive Mechanical Ventilation (MV) in patients with Cst <= 0.025 L/cm H2O
Number of subjects: 387

Group type: COMPARATOR
Intervention: Invasive Mechanical Ventilation (MV) in patients with Cst <= 0.025 L/cm H2O
Number of subjects: 387
Study: 16116046

Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide (160 mg/12.5 mg)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 482
Study: 12160563

Group type: EXPERIMENTAL
Intervention: Caffeine (100mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine-deprived group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 24
Study: 9576125

Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention (18-month duration)
Number of subjects: 377
Study: 8584772

Group type: EXPERIMENTAL
Intervention: General anesthesia with fentanyl (10 micrograms/kg initial dose, followed by 5 micrograms/kg/h infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: General anesthesia with 60% nitrous oxide in oxygen plus thoracic epidural block with bupivacaine 0.5%
Number of subjects: 14
Study: 2236433

Group type: EXPERIMENTAL
Intervention: beta‐adrenoceptor blockade (100 mg of atenolol)
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: atenolol with instruction that heart rate would decrease
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: atenolol with instruction that did not mention cardiovascular effects
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: cardiac aware subjects
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: cardiac unaware subjects
Number of subjects: 44
Study: 486932

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarettes (1.84 mg standard yield)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarettes (0.6 mg standard yield)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Medium-nicotine cigarettes (1.4 mg standard yield)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Puffing behaviour and 24-hour cigarette consumption
Number of subjects: 12
Study: 30497684

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 750-1000 mg/m2 daily
Number of subjects: 149

Group type: COMPARATOR
Intervention: Levamisole 2-2.5 mg/kg on alternate days
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Levamisole
Number of subjects: 149
Study: 27986549

Group type: EXPERIMENTAL
Intervention: Roux-en-Y bypass gastroplasty (Bariatric group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Roux-en-Y bypass gastroplasty (Bariatric Diabetic group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clinical treatment (Control group)
Number of subjects: 60
Study: 25504994

Group type: EXPERIMENTAL
Intervention: Nintedanib 50 mg twice daily for 14 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nintedanib 100 mg twice daily for 14 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily for 28 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nintedanib added to ongoing pirfenidone therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 50
Study: 23499605

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 3025

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3025
Study: 20135132

Group type: EXPERIMENTAL
Intervention: 25 μg estradiol vaginal tablets (group I)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 5 mg hyaluronic acid sodium salt vaginal tablets (group II)
Number of subjects: 42
Study: 19660851

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) based screening
Number of subjects: 162243

Group type: COMPARATOR
Intervention: Control group (non-screened)
Number of subjects: 162243
Study: 16734312

Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop with Dyract Seal
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop with Concise
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop with Visio‐Seal
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prompt‐L‐Pop with Helioseal
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional etch with Dyract Seal
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional etch with Concise
Number of subjects: 56
Study: 15119985

Group type: EXPERIMENTAL
Intervention: Quality assessment of meta-analyses of RCTs of pharmacotherapy for MDD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Quality assessment using QUOROM checklist
Number of subjects: 32
Study: 11402910

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg for 4 weeks
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg for 4 weeks
Number of subjects: 574
Study: 9436499

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 0
Study: 8429284

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 3304565

Group type: EXPERIMENTAL
Intervention: Lidocaine with fentanyl (100 mu)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine without fentanyl
Number of subjects: 0
Study: 31534560

Group type: EXPERIMENTAL
Intervention: Vitamin D3 treatment
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 448
Study: 29522710

Group type: EXPERIMENTAL
Intervention: 2 g/d vitamin C as a twice daily bolus infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 g/d vitamin C as continuous infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 g/d vitamin C as a twice daily bolus infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 g/d vitamin C as continuous infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 g/d vitamin C (all regimens)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 g/d vitamin C (all regimens)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Post-discontinuation of vitamin C
Number of subjects: 20
Study: 25969567

Group type: EXPERIMENTAL
Intervention: Lifestyle changes and guideline-based treatment according to ADA recommendations
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 77
Study: 24882434

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice daily
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 22585884

Group type: EXPERIMENTAL
Intervention: Pedometer step‐based Green Prescription
Number of subjects: 330

Group type: COMPARATOR
Intervention: Standard Green Prescription
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 330
Study: 20533635

Group type: EXPERIMENTAL
Intervention: All Bond 3 (BISCO, Inc)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: XP Bond (Dentsply)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond+Alloy Primer (Kuraray)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Kuraray DC Bond (Kuraray)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Xeno V (Dentsply)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Self-etch adhesives
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Etch & rinse adhesives
Number of subjects: 50
Study: 17645076

Group type: EXPERIMENTAL
Intervention: Intravenous laser radiation of blood (ILRB)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Antioxidant drug cytoflavin
Number of subjects: 130
Study: 15695307

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 109
Study: 12440352

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Antioxidant vitamin supplementation (vitamin E 600 mg/day, vitamin C 250 mg/day, betacarotene 20 mg/day)
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20536
Study: 9921566

Group type: EXPERIMENTAL
Intervention: Educational intervention (14-minute video and booklet on managing cancer pain)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (pain management instructions from office staff)
Number of subjects: 36
Study: 9019387

Group type: EXPERIMENTAL
Intervention: Etidocaine (15 mg/ml)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Bupivacaine (5 mg/ml) + Lidocaine (10 mg/ml)
Number of subjects: 112
Study: 2298903

Group type: EXPERIMENTAL
Intervention: Pronated position
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supinated position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 60
Study: 425848

Group type: EXPERIMENTAL
Intervention: sar1 ala8 angiotensin II (saralasin)
Number of subjects: 12
Study: 31718988

Group type: EXPERIMENTAL
Intervention: Guideline-based quality indicators (QIs) recommended in 35 of the 109 valid CPGs (32%).
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Guideline-based QIs from 11 randomly selected guidelines (5 medical societies, 1 DMG, 5 GGPO).
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Quantitative measures of QIs.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Quality objectives for QIs.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Assessment of quality of care based on QIs.
Number of subjects: 109
Study: 29169838

Group type: EXPERIMENTAL
Intervention: Lidocaine (260 mg of 2% lidocaine subcutaneously and intratesticularly 5 minutes prior to castration)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Meloxicam (0.5 mg kg−1 of meloxicam subcutaneously 30 minutes prior to castration)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no preoperative analgesia administered)
Number of subjects: 36
Study: 26512601

Group type: EXPERIMENTAL
Intervention: Peginterferon/ribavirin (P‐R) treatment
Number of subjects: 19
Study: 23269286

Group type: EXPERIMENTAL
Intervention: Anacetrapib (20mg and 150mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 0
Study: 21545859

Group type: EXPERIMENTAL
Intervention: Accountability
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Insight
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study: 19734458

Group type: EXPERIMENTAL
Intervention: Biomimetic remineralization scheme using Portland cement/simulated body fluid with polyacrylic acid and polyvinylphosphonic acid.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomimetic remineralization scheme.
Number of subjects: 0
Study: 17049640

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 152

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Ibutilide (for AF)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Amiodarone (for AF)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Ibutilide (for Af)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Amiodarone (for Af)
Number of subjects: 152
Study: 15476908

Group type: EXPERIMENTAL
Intervention: Tobramycin 3 mg/mL plus dexamethasone 1 mg/mL (TD)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/mL plus neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 6000 IU/mL (DNP)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Neomycin sulfate 3500 IU/mL plus polymyxin B sulfate 7500 IU/mL plus gramicidin 20 microg/mL (NPG)
Number of subjects: 271
Study: 11902023

Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Art therapy group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Overall participants (all groups)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 97
Study: 9493884

Group type: EXPERIMENTAL
Intervention: Daily inner cannula changes
Number of subjects: 60

Group type: COMPARATOR
Intervention: No inner cannula changes
Number of subjects: 60
Study: 8067499

Group type: EXPERIMENTAL
Intervention: Propranolol, 60 mg or less, administered daily between 5:30 and 6:00 a.m.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3052917

Group type: EXPERIMENTAL
Intervention: GIK cardioplegic solution with calcium and PGI2 analogue (OP-41483, 300 micrograms/l)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GIK cardioplegic solution with calcium (1.2 mM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Basic GIK cardioplegic solution alone (no added calcium)
Number of subjects: 18
Study: 31597806

Group type: EXPERIMENTAL
Intervention: Curcumin gel applied post-scaling and root planing (SRP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no curcumin gel)
Number of subjects: 10
Study: 28283490

Group type: EXPERIMENTAL
Intervention: GOPC medical treatment orders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 24625625

Group type: EXPERIMENTAL
Intervention: Tanezumab monotherapy (5 or 10 mg)
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: Tanezumab + NSAIDs (naproxen 500 mg twice daily or celecoxib 100 mg twice daily)
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Tanezumab (5 or 10 mg)
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Tanezumab + NSAIDs
Number of subjects: 2700
Study: 23287823

Group type: EXPERIMENTAL
Intervention: Postoperative APAP (autotitrating positive airway pressure)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study: 21982649

Group type: EXPERIMENTAL
Intervention: Canakinumab (50, 150, or 300 mg every 3 months, administered subcutaneously)
Number of subjects: 17200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17200
Study: 19238654

Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: atorvastatin 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 17174178

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 75
Study: 12900106

Group type: EXPERIMENTAL
Intervention: Decision-aided consultations
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine consultations
Number of subjects: 68
Study: 10882574

Group type: EXPERIMENTAL
Intervention: Enhanced‐potency inactivated poliovirus vaccine (E‐IPV) followed by monovalent oral poliovirus vaccine (OPV, type 3 Sabin)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Trypsin‐modified E‐IPV
Number of subjects: 66
Study: 8807623

Group type: EXPERIMENTAL
Intervention: Disodium monofluorophosphate (MFP) 13.2 mg/day + calcium (1,000 mg/day) + calcifediol (50 micrograms/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium (1,000 mg/day) + calcifediol (50 micrograms/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Historical control group (no specific therapeutic intervention for bone disease)
Number of subjects: 15
Study: 1360822

Group type: EXPERIMENTAL
Intervention: Fluid replacement guided by PscO2 measurements
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fluid replacement guided by clinical criteria
Number of subjects: 29
Study: 6586292

Group type: EXPERIMENTAL
Intervention: Interferon-alpha A (1 ng/ml)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Interferon-alpha D (1 ng/ml)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both interferon subtypes
Number of subjects: 8
Study: 31256445

Group type: EXPERIMENTAL
Intervention: Ascaris infection
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Wheezing prevalence
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Th1, Th2, and CD4 + CD25 + CD127low cells
Number of subjects: 1658
Study: 27933460

Group type: EXPERIMENTAL
Intervention: CRC screening barriers counseling call conducted by a lay health advisor (LHA) using an open-ended question to identify barriers without probes.
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: CRC screening barriers counseling call conducted by a lay health advisor (LHA) using a list of potential screening barriers with probes.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 109
Study: 27117223

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 2000 ml/h
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 1000 ml/h
Number of subjects: 300

Group type: COMPARATOR
Intervention: Propofol infusion at 500 ml/h
Number of subjects: 300
Study: 24018351

Group type: EXPERIMENTAL
Intervention: B-mode ultrasound with modified Seldinger technique (BUMST)
Number of subjects: 100
Study: 22192338

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 10744

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10744

Group type: EXPERIMENTAL
Intervention: Moderate weight loss (3-10 kg)
Number of subjects: 10744

Group type: EXPERIMENTAL
Intervention: Sibutramine and Placebo
Number of subjects: 10744
Study: 20061913

Group type: EXPERIMENTAL
Intervention: Steroid avoidance or withdrawal (SAW)
Number of subjects: 5637